Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir

Abstract In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance. These findings suggest that any association w...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2012-04, Vol.47 (4), p.475-481
Main Authors: de Niet, A., Takkenberg, R.B., Benayed, R., Riley-Gillis, B., Weegink, C.J., Zaaijer, H.L., Koot, M., Jansen, P.L.M., Beld, M.G.H.M., Lopatin, U., Reesink, H.W.
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
chronic hepatitis B
Cohort Studies
DNA, Viral - metabolism
Drug Therapy, Combination
Ethnicity - genetics
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Genetic Variation
HBsAg clearance
Hepatitis B e Antigens - immunology
hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - genetics
Hepatitis B, Chronic - immunology
Human viral diseases
Humans
IL28B
Infectious diseases
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Medical sciences
Organophosphonates - therapeutic use
Pharmacology. Drug treatments
Polyethylene Glycols - therapeutic use
Polymorphism, Single Nucleotide - genetics
Prospective Studies
Recombinant Proteins - therapeutic use
rs12979860 polymorphism
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance. These findings suggest that any association with outcome, if present, is less than that seen in chronic hepatitis C. Additional studies are needed to enlarge sample size and to refine our understanding of IL28B biology in the context of chronic hepatitis B response to immunomodulatory and direct antiviral therapy.
ISSN:0036-5521
1502-7708
DOI:10.3109/00365521.2011.648952